Paeds Vivas · endocrinology-diabetes-and-growth
Type 1 diabetes: diagnosis and initial management — branching viva
Branching viva from the alert child with new hyperglycaemia — through the diagnostic glucose thresholds, the bedside exclusion of ketoacidosis, the autoantibodies and C-peptide that name the type, the first subcutaneous basal-bolus insulin regimen and family education, the honeymoon phase and the never-stop-insulin rule, to the infant under six months and the antibody-positive relative in the screening era.
On this page
Study tools
Target exams
Branch 1 — Opening: confirm and triage
Examiner: "A six-year-old has two weeks of thirst, polyuria and weight loss and a finger-prick glucose of 22 mmol/L. How do you confirm the diagnosis, and what is the single most important thing you must decide next?" [2]
Expected: The diagnosis of diabetes is confirmed on glucose — a random level of 11.1 mmol/L or higher with symptoms (met here), a fasting level of 7.0 or higher, or an HbA1c of 48 mmol/mol (6.5 percent) or higher. The most important next decision is whether the child has ketoacidosis, because that changes the whole pathway. [2] [1]
Branch probes (examiner selects based on the answer): [1]
- If the candidate confirms and triages well, state how you exclude ketoacidosis: measure capillary or blood ketones with venous pH and bicarbonate, and assess hydration, conscious level and breathing. [1]
- If the candidate wants to wait for antibody results before treating, correct them: the diagnosis is made on glucose alone and treatment must not wait for the type-defining tests. [4]
References5ShowHide
- [1]DiMeglio LA; Evans-Molina C; Oram RA Type 1 diabetes. Lancet, 2018.PMID 29916386
- [2]de Bock M; Agwu JC; et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets. Horm Res Paediatr, 2024.PMID 39701064
- [3]Cengiz E; Danne T; et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes. Horm Res Paediatr, 2024.PMID 39884261
- [4]Leighton E; Sainsbury CA; Jones GC A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther, 2017.PMID 28484968
- [5]Herold KC; Bundy BN; et al An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med, 2019.PMID 31180194